Literature DB >> 16690931

Bovine respiratory syncytial virus lacking the virokinin or with a mutation in furin cleavage site RA(R/K)R109 induces less pulmonary inflammation without impeding the induction of protective immunity in calves.

J-F Valarcher1, J Furze, S G Wyld, R Cook, G Zimmer, G Herrler, G Taylor.   

Abstract

The BRSV fusion (F) protein is cleaved at two furin consensus sequence sites, resulting in the generation of disulphide-linked F1 and F2 subunits and the release of an intervening peptide of 27 amino acids (pep27), which is converted into a biologically active tachykinin (virokinin). The role of the virokinin and the importance of one of the furin cleavage sites, FCS-2 [RA(R/K)R109], in the pathogenesis of BRSV infection and in the subsequent development of immunity was studied in gnotobiotic calves infected with a recombinant BRSV (rBRSV) lacking pep27 (rBRSVdelta p27) or with rBRSV108/109, which contains two amino acid substitutions in FCS-2 (RANN109). Although replication of the mutant viruses and the parental wild-type (WT) rBRSV in the lungs was similar, the extent of gross and microscopic lesions induced by the mutant viruses was less than that induced by WT rBRSV. Furthermore, the numbers of eosinophils in the lungs of calves infected with the mutant viruses were significantly less than that in calves infected with WT virus. These observations suggest a role for the virokinin in the pathogenesis of BRSV infection. Following mucosal immunization with rBRSVdelta p27, the levels of BRSV-specific serum antibodies were similar to those induced by WT virus. In contrast, the level of neutralizing antibodies induced by rBRSV108/109 was 10-fold lower than that induced by WT virus. Nevertheless, resistance to BRSV challenge induced by the mutant and WT viruses was similar, suggesting that neither pep27 nor FCS-2 plays a major role in the induction of protective immunity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16690931     DOI: 10.1099/vir.0.81755-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  7 in total

1.  Differential sensitivity of differentiated epithelial cells to respiratory viruses reveals different viral strategies of host infection.

Authors:  Katherina Goris; Sabine Uhlenbruck; Christel Schwegmann-Wessels; Wiebke Köhl; Frank Niedorf; Michael Stern; Marion Hewicker-Trautwein; Robert Bals; Geraldine Taylor; Armin Braun; Gerd Bicker; Manfred Kietzmann; Georg Herrler
Journal:  J Virol       Date:  2008-12-03       Impact factor: 5.103

Review 2.  Understanding the mechanisms of viral induced asthma: new therapeutic directions.

Authors:  Nicole G Hansbro; Jay C Horvat; Peter A Wark; Philip M Hansbro
Journal:  Pharmacol Ther       Date:  2008-01-29       Impact factor: 12.310

3.  Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites.

Authors:  Sandrine Belouzard; Victor C Chu; Gary R Whittaker
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-24       Impact factor: 11.205

4.  Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein.

Authors:  Jean Kaoru Millet; Gary R Whittaker
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-06       Impact factor: 11.205

5.  Proteolytic activation of the spike protein at a novel RRRR/S motif is implicated in furin-dependent entry, syncytium formation, and infectivity of coronavirus infectious bronchitis virus in cultured cells.

Authors:  Yoshiyuki Yamada; Ding Xiang Liu
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

Review 6.  Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis.

Authors:  Jean Kaoru Millet; Gary R Whittaker
Journal:  Virus Res       Date:  2014-11-22       Impact factor: 3.303

Review 7.  Biology of Infection and Disease Pathogenesis to Guide RSV Vaccine Development.

Authors:  Seyhan Boyoglu-Barnum; Tatiana Chirkova; Larry J Anderson
Journal:  Front Immunol       Date:  2019-07-25       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.